ViiV/Janssen's Long-Acting Anti-HIV Injections Impress
A dual regimen consisting of long-acting injectable formulations of the integrase inhibitor cabotegravir and the nnRTI rilpivirine was as effective as the oral standard-of-care regimen of three drugs daily, in interim results from the ATLAS study.
You may also be interested in...
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.
ViiV CEO predicts strong pipeline and two-drug strategy will reinforces group's HIV market position and put it ahead of Gilead by the mid-2020s.
Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.